Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like this company has been form nov 8. See some post below.
Hope so!
Wait & see.
Agree.
Some takes profit I guess.
Ok it's not a credible video, he is not competent. Sorry guy!
Oncoceutic in not the same as Canary O.
Forget this post.
I mix both company name.
Better that I return in mute mode! Lol
oopppss I thought it might be an interesting video..
Mistake!
The video not good?
I did not watch completely.
I thought is was a resume of the latest news.
https://www.globenewswire.com/news-release/2021/01/08/2155451/25619/en/Chimerix-Acquires-Oncoceutics-to-Expand-Pipeline-with-Late-Stage-Oncology-Program.html
Chimerix acquires Oncoceutics Jan 2021.
???
Watch on "you tube"
"A lot of scared investors here."
Why are they scare? Because what it says in the 8k?
Looks like good news to me.
Looks like those MM are not serious investors.
Not for the long term for sure.
Patience!
It's always like that..good news...down :(
Looks like some control shares price.
When we will get ride of them?
Time to buy?
Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
AccessWire - 1 hour ago
WAKEFIELD, MA / ACCESSWIRE / November 11, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported topline results from the Company's Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-19. Brilacidin is being developed for treatment of COVID-19 under FDA Fast Track designation.
Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study's primary endpoint based on clinical status. Clinical status endpoints contain a degree of subjectivity that may impact outcomes of COVID-19 trials. Additional analysis of topline and all study endpoints is ongoing.
"Though disappointed with these topline results, treating moderate-to-severe COVID-19 is an exceptionally difficult patient population," said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "Companies, such as Merck and Regeneron, also did not show clinical benefit in these groups of patients, although both went on to refocus their development efforts in mild-to-moderate COVID-19 and achieve success. Regarding our Brilacidin antiviral program in general, collaborations with NIH scientists and academic researchers to explore Brilacidin's broad-spectrum antiviral activity in different viruses are ongoing. Initial feasibility work to formulate Brilacidin for potential prophylactic use via inhaled delivery, to leverage Brilacidin's unique virucidal and blocking antiviral properties, also is underway. There are many paths to pursue in the antiviral space. We believe Brilacidin holds tremendous promise as a differentiated antiviral drug candidate and plan to continue its development in this area of great opportunity and unmet need."
Topline safety data showed Brilacidin was generally well-tolerated, with frequency of treatment-emergent adverse events similar between study arms. The number of patients who died totaled eight, four each between active and placebo. The overall mortality rate (6.67%) in the trial was approximately one-half of what is typically observed in this patient population.
The randomized, double-blind, placebo-controlled trial (see NCT04784897) evaluated the efficacy and safety of intravenous Brilacidin administered for 3 or 5 days in addition to standard of care. In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug. Patients were evenly split between male and female, with a majority categorized as experiencing severe COVID-19 at baseline. Most patients were under 65 years old, with an average age of 58.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its potential impact on SARS-CoV-2 (COVID-19) and other viruses. Other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals for Brilacidin and Kevetrin in the United States and other jurisdictions, including without limitation that the Company's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company's filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company's ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACTS:
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
SOURCE: Innovation Pharmaceuticals
Correction: Leigh H. not Leigh L.
When I saw the title, I thought Leigh L. came back with NGW!
Wondering how he is doing.
Ooopss..sorry, it's an old article May 2019 (don't know why it was on Globe/Mail today???)
"CEO Leigh Hughes buying as Next Green Wave Holdings comes off its highs."
Unfortunately I cannot copy the article, I am not a member of Globe and Mail, but if some have a subscription, please share.
RGBP Stock: Something Brewing?
Derrick Thomas
Written by Derrick Thomas
Posted on November 5, 2021 7 min read
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) is a biotechnology company focusing on the immunology and immunotherapy space. RGBP specializes in small molecule therapies for treating cancer and autoimmune disorders. The company has been the subject of buyout speculation for some time thanks in part to its definitive agreement with Eli Lilly (NYSE:LLY). But more recent news moved RGBP stock up 60% since November 1st.
Catalysts
RGBP has made significant progress since the last article, as it was issued a patent for its “Universal Donor Checkpoint Inhibitor Silenced/Gene Edited Cord Blood Killer Cells” in October. Essentially this patent covers RGBP’s invention of treatments that induce an “anticancer” response in patients. It’s therapeutic use triggers an antitumor immune response from the body which has the potential to be revolutionary for the company.
The company seems to be building on two successful deals with Oncology Pharma from earlier this year as it sets out on the path for commercializing some of its research. In October it gave a Scope of Work order to Biotech Research Group to help the company strategize ways to commercialize its NR2F6 intellectual property. RGBP’s NR2F6 nuclear receptor was identified as a potential immune cell inhibitor that can help trigger the immune system to fight cancer as well as autoimmunity diseases and chronic inflammation.
This is the same group hired by RGBP in May to revive its inactive INDs granted in 2015 by the FDA for the company to begin clinical trials for its HemaXellerate cell therapy. Some are expecting an announcement related to its INDs this November and the anticipation seems to be stirring up RGBP’s stock.
It also seems RGBP has been cleaning house after settling a convertible note equivalent to $43,529 with the noteholder. But the company has evidently been on campaign to pay off its debts for several months now, paying off $967,830 in convertible notes and $539,392 in other fees through the issuance of roughly 706 common shares and 23.7 million Series A Preferred shares. This appears to have nearly erased the company’s convertible debt except one note which is due June of 2022.
Meanwhile the company has made at least two agreements with Oncology Pharma giving the latter the exclusive right to develop and commercialize IP related to the treatment of cancer. In October, RGBP agreed to provide Oncology with intellectual property related to the mRNA used to treat pancreatic cancer. In exchange, RGBP received a fee of $55,000, and will take 5% royalties in net sales as well as 10% of all consideration from sublicensees.
This has led some to speculate that RGBP could be an acquisition target for Oncology. But Precigen was also rumored to be a buyout candidate as well due to Precigen’s CEO – Helen Sabzevari – former role on RGBP’s Scientific Advisory Board. Another potential target could be Eli Lilly which has maintained a very good working relationship with RGBP for 5 years.
Beginning in 2016 with a definitive agreement allowing Regen to receive compounds from Lilly for drug discovery purposes and exchange information of mutual interest, the two companies have since covered a lot of ground together. In 2017, Eli Lilly’s former Eli Executive led RGB’s newly formed Business Advisory Board. Because there is a Drug Discovery Pact between both parties, some are wondering if RGBP may be a target for the massive company.
In any case, RGBP is largely believed to be an eventual acquisition candidate for a pharma company due to its impressive array of patents. The stock’s recent activity definitely seems to be hinting that whales are moving behind the scenes.
Media sentiment
Thanks @Weezus420 for breaking down the differences between RGBP stock and RGBPP stock – both which will move on the same catalysts.
Let's compare $RGBP share structure to $RGBPP…
Remember $DWAC and $DWACW?
Similar situation imo.
175 MILLION DTC vs 4 BILLION DTC
23x smaller float
What do you think is undervalued?
RGBP is up 17%, RGBPP is up .65%
RGBP market cap $100 million
RGBPP market cap $34 million pic.twitter.com/11oUp9F1NR
— ??Weezus?? (@Weezus420) November 5, 2021
Technical Analysis
RGBP stock chart
After spiking 60%, RGBP stock is trading at $.0258 with a support at .0236 and .0200. It is testing its resistance .0266 and if it breaks through, the next point of resistance could be near .0338. The MACD had a bullish crossover and is still trending upwards with no sign of a second crossover and the RSI is near 65 due to increased interest. Accumulation spiked up following a general downtrend as is typical of biotech stocks which move on binary events.
Should You Buy
With its most recent patent and numerous activities, RGBP seems to have something in the works. When an announcement is released investors will know definitively where the company is heading next, but speculation has excited many investors regarding the company’s prospects. In the short-term, this could cause a further spike in the stock but RGBP could also present a lucrative long-term hold for bullish investors. If its INDs are renewed or new paths for commercialization of its products are revealed, RGBP could be set to close out the year on a high. As is, if RGBP stock breaks through its current resistance near $.0266 then it could shoot up to $.03 and beyond.
Disclaimer
Please visit and read our disclaimer here.
You can also join our free alerts room and Twitter for the best stock alerts out there.
Don’t forget we have a Youtube Channel with at least biweekly releases on the latest and greatest runners!
Exactly!
That's right!
I am holding of course..the best is coming!
But it starts to be said on stock market sites, which is great!
"...RGBP CAN BE ACQUIRE BY A LARGER COMPANY..."
$IPIX $NWBO $RGBP $SYSX new article and video just released!!https://t.co/51tDfL8tSA
— Insider Financial (@InsidrFinancial) November 5, 2021
"Things are moving at Regen, and we expect more and more updates to come soon. Eventually, RGBP can be acquired by a larger company, like Oncology or Precigen, but even on its own Regen is a great OTC stock to hold."
$IPIX $NWBO $RGBP $SYSX new article and video just released!!https://t.co/51tDfL8tSA
— Insider Financial (@InsidrFinancial) November 5, 2021
Good! I might add more too.
Finally, I will not sale amy shares, will buy more on a dip.
Safety first!
Getting high all week, should we expect profit taking soon and a drop?
Wondering if I should take profit, and buy again on a low.
Hum..food for thought!
Thanks for your input..interesting.
I'll continue to track NGW.
I know..it's not fun.
I wait 2 years before making profit.
I might buy again..not sure yet.
About you..how do you see NGW stock will do in couple of months, years?
Just curious..
But really, I hope we reach the lower floor and it will goes up next couple of months!
Lots of buyers this morning.
Nov till Feb are good months for stock market, NGW can only goes up now (if lower floor has been reach).
I think I will re invest.
Of course sometimes I am having doubt about RGBP (I am not alone!), specially when the stock continue to go low.
But believe it or not, I am keeping my shares and I cross my fingers!
That's all I can do!
I am still holding..waiting for better days!
They will come!
Not fun to watch for sure but... hold tight!
Hum..not really up to date!